Loading
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Previous close
$6.18
−$0.07 · -1.12%
Pre-market
$6.15
−$0.03 · -0.49%
Oct 8, 8:35 AM ET
Regular session · ET · Market data may be delayed.
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Day range
Current $6.18
52-week range
Current $6.18
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
31
Expensive
Sentiment
58
Mixed
Risk
77
High Risk
Momentum
47
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Day range
Current $6.18
52-week range
Current $6.18
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 24.99M USD | 9.73M USD |
| Cost of goods sold | 6.38M USD | — | — | — | — |
| Gross profit | −6.38M USD | — | — | 24.99M USD | 9.73M USD |
| Research and development | 99.13M USD | 99.32M USD | 106.04M USD | 71.25M USD | 48.94M USD |
| Selling, general, and administrative | 22.99M USD | 28.29M USD | 26.53M USD | 26.3M USD | 22.22M USD |
| Operating expenses | 115.73M USD | 127.62M USD | 152.04M USD | 97.54M USD | 71.16M USD |
| Interest income | 5.78M USD | 10.71M USD | 9.98M USD | 3.76M USD | 91K USD |
| Interest expense | 36K USD | 4K USD | 25K USD | 80K USD | 176K USD |
| Depreciation and amortization | 6.38M USD | 6.47M USD | 6.1M USD | 2.67M USD | 1.54M USD |
| Operating income | −122.11M USD | −127.62M USD | −152.04M USD | −72.55M USD | −61.43M USD |
| Net income | −116.8M USD | −117.12M USD | −142.66M USD | −69.79M USD | −62M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$27.00
336.89% upsideCash distributions grouped by calendar year; partial years are marked.
$0.26
2017 complete year+13.0% since 2013
$0.23
2,013
$0.24
2,014
$0.24
2,015
$0.25
2,016
$0.26
2,017
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Sep 21, 2018 | $0.0001Quarterly | Sep 24, 2018 | Oct 9, 2018 |
Dividend | Jun 7, 2018 | $0.0001Quarterly | Jun 8, 2018 | Jun 22, 2018 |
Dividend | Mar 8, 2018 | $0.0006Quarterly | Mar 9, 2018 | Mar 23, 2018 |
Dividend | Dec 15, 2017 | $0.0006Quarterly | Dec 18, 2017 | Dec 28, 2017 |
Dividend | Sep 7, 2017 | $0.0006Quarterly | Sep 8, 2017 | Sep 21, 2017 |
Dividend | Jun 7, 2017 | $0.0006Quarterly | Jun 9, 2017 | Jun 23, 2017 |
Ex-dividend Sep 21, 2018
$0.0001
Quarterly
Record Sep 24, 2018 · Payment Oct 9, 2018
Ex-dividend Jun 7, 2018
$0.0001
Quarterly
Record Jun 8, 2018 · Payment Jun 22, 2018
Ex-dividend Mar 8, 2018
$0.0006
Quarterly
Record Mar 9, 2018 · Payment Mar 23, 2018
Ex-dividend Dec 15, 2017
$0.0006
Quarterly
Record Dec 18, 2017 · Payment Dec 28, 2017
Ex-dividend Sep 7, 2017
$0.0006
Quarterly
Record Sep 8, 2017 · Payment Sep 21, 2017
Ex-dividend Jun 7, 2017
$0.0006
Quarterly
Record Jun 9, 2017 · Payment Jun 23, 2017
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI2.12M0.00%2.3T USD0.03%$381.03-0.40%
Vanguard Extended Market ETFVXF860.53K0.00%95.4B USD0.05%$233.49-1.56%
iShares Micro-Cap ETFIWC141.75K0.01%1.33B USD0.60%$183.36-1.09%
Dimensional - US Small Cap ETFDFAS116.44K0.00%33.66B USD0.31%$77.92-1.38%
U.S. Micro Cap Portfolio ETFDFMC108.29K0.00%7.52B USD0.43%$57.50-1.29%
Avantis U.S. Small Cap Equity ETFAVSC41.24K—3.08B USD0.25%$69.63-1.18%
U.S. Vector Equity Portfolio ETF Class SharesDXUV2.99K0.00%6.16B USD0.26%$67.96-0.64%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCAvantis U.S. Small Cap Equity ETFAVSCU.S. Vector Equity Portfolio ETF Class SharesDXUVAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
